Verastem

Verastem, Inc. (NASDAQ: VSTM) is a biopharmaceutical company focused on drug discovery and development to improve outcomes for cancer patients. Verastem is currently developing Duvelisib, a dual inhibitor of PI3K-Delta and PI3K-Gamma, which successfully met its primary endpoint in a Phase 2 study in iNHL and is currently being evaluated in a Phase 3 clinical trial in patients with CLL. Verastem is also developing the FAK inhibitor defactinib, which is currently being investigated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various types of cancer, including pancreatic cancer, ovarian cancer, non-small cell lung cancer and mesothelioma. Verastem's product candidates seek to treat cancer by modulating the local tumor microenvironment, improving anti-tumor immunity, and reducing cancer stem cells.